Protection of mice from wild-type Sendai virus infection by a trypsin-resistant mutant, TR-2.

AUTOR(ES)

Tashiro, M

RESUMO

A trypsin-resistant mutant of Sendai virus, TR-2, which could be activated by chymotrypsin but not by trypsin or the protease present in mouse lung, was inoculated intranasally into mice after being activated in vitro. TR-2 hardly brought about clinical illness or lung lesions in mice; the protease present in the lung could not activate the progeny virus, and the infection terminated after one-step replication. Nevertheless, the immunoglobulin A antibody against wild-type Sendai virus was produced in the respiratory tracts as well as the serum immunoglobulin G antibody, and the mice were protected from the challenge of the wild-type Sendai virus. On the basis of these results, TR-2 may provide a new model of live vaccine for paramyxoviruses; its availability as a live vaccine is also discussed.

Documentos Relacionados

• Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors.
• Cell-mediated immunity induced in mice after vaccination with a protease activation mutant, TR-2, of Sendai virus.
• Pneumopathogenicity in mice of a Sendai virus mutant, TSrev-58, is accompanied by in vitro activation with trypsin.
• Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant.
• Deoxyribonucleic Acid Polymerase of Wild-Type and Phosphonoacetic Acid-Resistant Mutant of Herpes Simplex Virus